Drug Shortage Report for TEVA-SPIRONOLACTONE/HCTZ
Report ID | 128022 |
Drug Identification Number | 00613231 |
Brand name | TEVA-SPIRONOLACTONE/HCTZ |
Common or Proper name | SPIRONOLACTONE HCTZ 25/25MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | SPIRONOLACTONE HYDROCHLOROTHIAZIDE |
Strength(s) | 25MG 25MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 100 |
ATC code | C03EA |
ATC description | DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-11-04 |
Estimated end date | 2021-02-28 |
Actual end date | 2021-02-04 |
Shortage status | Resolved |
Updated date | 2021-02-05 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2021-02-05 | French | Compare |
v7 | 2021-02-05 | English | Compare |
v6 | 2021-01-21 | French | Compare |
v5 | 2021-01-21 | English | Compare |
v4 | 2021-01-07 | French | Compare |
v3 | 2021-01-07 | English | Compare |
v2 | 2020-11-06 | French | Compare |
v1 | 2020-11-06 | English | Compare |
Showing 1 to 8 of 8